Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

β-adrenergic receptor, amyloid β-peptide, and Alzheimer's disease.

Wang D, Xiang YK.

Curr Top Membr. 2011;67:205-28. doi: 10.1016/B978-0-12-384921-2.00010-0. Review. No abstract available.

PMID:
21771492
2.

Anti-amyloid treatments in Alzheimer's disease.

Sapra M, Kim KY.

Recent Pat CNS Drug Discov. 2009 Jun;4(2):143-8. Review.

PMID:
19519562
3.

Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease.

Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A.

Mol Neurobiol. 2012 Dec;46(3):605-13. doi: 10.1007/s12035-012-8313-6. Epub 2012 Aug 12. Review.

PMID:
22886436
4.

[Formation and participation of nano-amyloids in pathogenesis of Alzheimer's disease and other amyloidogenic diseases].

Mal'tsev AV, Galzitskaia OV.

Biomed Khim. 2010 Nov-Dec;56(6):624-38. Review. Russian.

PMID:
21395066
5.

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Haass C, Selkoe DJ.

Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12. Review.

PMID:
17245412
6.

Dysfunction of TGF-beta signaling in Alzheimer's disease.

Das P, Golde T.

J Clin Invest. 2006 Nov;116(11):2855-7.

7.

A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease.

Parthsarathy V, McClean PL, Hölscher C, Taylor M, Tinker C, Jones G, Kolosov O, Salvati E, Gregori M, Masserini M, Allsop D.

PLoS One. 2013;8(1):e54769. doi: 10.1371/journal.pone.0054769. Epub 2013 Jan 31. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/57e0a947-8600-4658-b04c-cf7a45c8bd8d.

8.

Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease.

Selkoe DJ.

Handb Clin Neurol. 2008;89:245-60. doi: 10.1016/S0072-9752(07)01223-7. Review. No abstract available.

PMID:
18631749
9.

Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.

Larbanoix L, Burtea C, Ansciaux E, Laurent S, Mahieu I, Vander Elst L, Muller RN.

Peptides. 2011 Jun;32(6):1232-43. doi: 10.1016/j.peptides.2011.04.026. Epub 2011 May 6.

PMID:
21575663
10.

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Yan SD, Bierhaus A, Nawroth PP, Stern DM.

J Alzheimers Dis. 2009;16(4):833-43. doi: 10.3233/JAD-2009-1030. Review.

11.

[Development of therapies of Alzheimer's disease].

Shoji M.

Nihon Ronen Igakkai Zasshi. 2003 Sep;40(5):473-5. Review. Japanese. No abstract available.

12.

Quantifying an amyloid β model for Alzheimer's disease.

Schneider LS.

Lancet Neurol. 2013 Apr;12(4):327-8. doi: 10.1016/S1474-4422(13)70050-4. Epub 2013 Mar 8. No abstract available.

PMID:
23477990
13.

Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease.

Zetterberg H, Blennow K.

Alzheimers Dement. 2013 Jul;9(4):459-62. doi: 10.1016/j.jalz.2012.07.002. Epub 2012 Nov 14. Review.

PMID:
23159047
14.

Is an effective immune intervention for Alzheimer's disease in prospect?

Esiri MM.

Trends Pharmacol Sci. 2001 Jan;22(1):2-3.

PMID:
11165659
15.

34 GHz pulsed ENDOR characterization of the copper coordination of an amyloid β peptide relevant to Alzheimer's disease.

Kim D, Kim NH, Kim SH.

Angew Chem Int Ed Engl. 2013 Jan 21;52(4):1139-42. doi: 10.1002/anie.201208108. Epub 2012 Dec 3. No abstract available.

PMID:
23208892
16.

Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains.

Lasagna-Reeves CA, Kayed R.

FEBS Lett. 2011 Oct 3;585(19):3052-7. doi: 10.1016/j.febslet.2011.08.027. Epub 2011 Aug 24.

17.

The immune system, amyloid-beta peptide, and Alzheimer's disease.

Weksler ME, Gouras G, Relkin NR, Szabo P.

Immunol Rev. 2005 Jun;205:244-56. Review.

PMID:
15882358
18.
19.

Next generation therapeutics for Alzheimer's disease.

Bredesen DE, John V.

EMBO Mol Med. 2013 Jun;5(6):795-8. doi: 10.1002/emmm.201202307. Epub 2013 May 23.

20.

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D.

Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.

PMID:
23943781

Supplemental Content

Support Center